Effects of a prostaglandin DP receptor agonist, AL-6598, on aqueous humor dynamics in a nonhuman primate model of glaucoma.

@article{Toris2006EffectsOA,
  title={Effects of a prostaglandin DP receptor agonist, AL-6598, on aqueous humor dynamics in a nonhuman primate model of glaucoma.},
  author={C. Toris and G. Zhan and M. Feilmeier and C. Camras and M. Mclaughlin},
  journal={Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics},
  year={2006},
  volume={22 2},
  pages={
          86-92
        }
}
  • C. Toris, G. Zhan, +2 authors M. Mclaughlin
  • Published 2006
  • Chemistry, Medicine
  • Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
This study examines, in 11 cynomolgus monkeys with unilateral laser-induced glaucoma, the ocular hypotensive mechanism of action of AL-6598, partial agonist at the DP and EP prostanoid receptors. In a crossover fashion, both eyes of each monkey were dosed twice daily with 25 microL of either AL-6598 0.01% or vehicle for 2 days and on the morning of the 3rd day. Measurements were made on day 3 of each treatment. Alternative treatments were separated by at least 2 weeks. Intraocular pressures… Expand
Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow.
TLDR
The EP(4) receptor agonist 3,7-dithia PGE(1) is a highly efficacious IOP-lowering drug in monkeys that has no effect on uveoscleral outflow but does increase total outflow facility, which accounts for a substantial proportion of the ocular hypotensive activity. Expand
Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction.
TLDR
Recent animal and clinical studies of the effects of topical prostaglandin analogs on aqueous humor dynamics and recent cellular and molecular studies designed to clarify the outflow effects are summarized. Expand
Prostanoid Receptor Antagonist Effects on Intraocular Pressure, Supported by Ocular Biodisposition Experiments.
TLDR
It appears from these monkey studies, supported by rabbit ocular bioavailability data, that an absence of drug effect in the eye cannot be adequately substantiated without determination of ocular pharmacokinetics. Expand
Potential for serotonergic agents to treat elevated intraocular pressure and glaucoma: focus on 5-HT2 receptor agonists
TLDR
The ocular serotonergic literature pertaining to elevated IOP in patients with ocular hypertension and glaucoma, the data on ocular hypotensive serotonin-2 agonists, and their potential mechanism(s) of action at the cellular and whole-animal level are reviewed. Expand
Prostaglandins in the eye: Function, expression, and roles in glaucoma
TLDR
The modes of action of each of the prostaglandin molecules, their expression, their role in aqueous humour production and outflow within the eye, as well as their roles as medications for the treatment of glaucoma are examined. Expand
Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes.
TLDR
Data indicate that cabergoline's most prominent agonist activity involves activation of 5HT(2),5HT(1A), and D(2/3) receptors, and Cabergoline was an efficacious IOP-lowering agent in normotensive Brown Norway rats. Expand
Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 – 2018)
TLDR
There has been a growing awareness over recent years of the therapeutic use of novel derivatives as new antiglaucoma pharmaceutical products and many patents describing new compounds acting on different prostaglandin receptors, and mainly targeting EP1-4 and FP receptors, were released. Expand
Aqueous humor flow rate in normal cats and the effect of topical 2% dorzolamide on aqueous humor flow and intraocular pressure
Objective To establish the aqueous humor flow rate in normal cats via fluorophotometry, utilizing a noninvasive method previously established in other species and to evaluate the effect of topical 2%Expand
Chapter 7 Aqueous Humor Dynamics I
Publisher Summary Intraocular pressure (IOP) is maintained by the dynamics of ocular aqueous humor that involves its secretion, circulation throughout the anterior chamber, and drainage into theExpand
Non-continuous measurement of intraocular pressure in laboratory animals.
TLDR
A review of this subject matter is timely and should prove useful to others who wish to perform similar measurements, and the general principles underlying various types of tonometric and non-tonometric techniques for non-continuous determination of IOP are considered. Expand
...
1
2
...

References

SHOWING 1-10 OF 56 REFERENCES
Effects of PhXA41, A New Prostaglandin F2α Analog, on Aqueous Humor Dynamics in Human Eyes
TLDR
PhXA41, a new phenyl-substituted analog of a prostaglandin F 2α (PGF 2α ) prodrug, is an effective ocular hypotensive agent in patients with glaucoma as well as other parameters of aqueous humor dynamics. Expand
Effects of Travoprost on Aqueous Humor Dynamics in Monkeys
TLDR
Travoprost reduces IOP in normotensive monkey eyes by increasing uveoscleral outflow, and the IOP reduction in hypertensive eyes is probably via the same mechanism, although the increased uveOScleral drainage did not reach statistical significance. Expand
The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes.
TLDR
PhXA41 is a potentially useful ocular hypotensive agent that enhances the egress of aqueous humor via both major outflow pathways, suggesting that this agent has promise for the treatment of chronic glaucoma. Expand
The DP‐Receptor Agonist SQ27986 Raises but Does Not Lower Intraocular Pressure in Ocular Normotensive Monkeys
TLDR
The inability of SQ27986 to reduce IOP in ocular normotensive monkeys suggests that DP-receptor stimulation does not increase uveoscleral outflow or play a major role in IOP reduction by other relatively nonselective prostaglandins such as PGF2α. Expand
Multiple dosing of prostaglandin F2 alpha or epinephrine on cynomolgus monkey eyes. I. Aqueous humor dynamics.
TLDR
Whereas PGF2 alpha did not alter pupil size, epinephrine caused significant pupillary dilation, which did not appear to be secondary to diurnal fluctuations, repeated tonometry, experimental manipulation, or inadvertent drug transfer. Expand
Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics.
TLDR
AGN 192024 is an ocular hypotensive agent that works by enhancing both pressure-sensitive and pressure-insensitive aqueous humor outflow without diminishing aqueously humor formation. Expand
Effects of topical PGF2α on aqueous humor dynamics in cynomolgus monkeys
Single topical applications of prostaglandin F2 alpha (PGF2 alpha) tromethamine salt to living cynomolgus monkey eyes reduced intraocular pressure (IOP). Twice daily topical application was far moreExpand
Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes.
TLDR
The present study suggests that UF-021 has potential as a safe and effective ocular hypotensive drug with a mechanism of action different from other drugs currently available for the treatment of glaucoma. Expand
Effect of topical prostaglandin D2 on the aqueous humor dynamics in rabbits
TLDR
Results indicate that IOP reduction caused by topically applied prostaglandin (PG) D2 application is due mostly to the inhibition of aqueous flow rate. Expand
Prostaglandin F2 alpha-isopropylester eye drops: effects in normal human eyes.
TLDR
The effects of PGF2 alpha-isopropylester eye drops on intraocular pressure (IOP) and aqueous humour dynamics were investigated in healthy male volunteers and a slight miosis of 1 mm was seen in three of six eyes treated with 10 micrograms. Expand
...
1
2
3
4
5
...